Literature DB >> 8337821

IgG neutralization of type A influenza viruses and the inhibition of the endosomal fusion stage of the infectious pathway in BHK cells.

M C Outlaw1, N J Dimmock.   

Abstract

We have used three strains of type A influenza virus (A/fowl plaque virus/Rostock/34: H7N1; A/PR/8/34: H1N1; A/X31: H3N2) labeled with the fluorescent probe octadecyl rhodamine B chloride (R18) to study how neutralizing monoclonal IgG, specific for the haemagglutinin, affects the interaction of virus with BHK-21 cells. R18 labels viral lipid and self-quenches in the virion; dilution of R18 by fusion of viral and cellular membranes or by dissolution in detergent activates fluorescence. IgG neutralization reduced attachment to BHK-21 cells to an extent which depended on the virus-antibody concentration, but in no case was the inhibition of virus attachment to cells sufficient to fully account for the amount of neutralization obtained. The majority (> 78%) of attached IgG-neutralized virus became resistant to release by neuraminidase which indicated it was internalized by the cell. The endosomal fusion ability of IgG-neutralized virus which became cell-associated was also inhibited, to an extent which depended on the virus-antibody permutation. Inhibition of endosomal fusion, which is responsible for primary uncoating, was corroborated by immunofluorescence studies which showed that the NP antigen of IgG-neutralized virus, unlike that of infectious virus, did not accumulate in the nucleus. The loss of infectivity attributable to the combined inhibition of attachment and inhibition of fusion was sufficient to account for the extent of neutralization caused by relatively low concentrations of IgG (1/e or 63% neutralization). However it could not, with two possible exceptions, account for the neutralization resulting from higher concentrations of IgG (sufficient to cause > 99.9% neutralization), and we conclude that at least one other mechanism is operating simultaneously, such as that described by Rigg et al., (1989, J. Gen. Virol. 70, 2097-2109).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8337821     DOI: 10.1006/viro.1993.1391

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

Review 1.  Genetic and structural determinants of virus neutralizing antibodies.

Authors:  J E Crowe; R O Suara; S Brock; N Kallewaard; F House; J H Weitkamp
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab')2 fragments.

Authors:  F Ramisse; F X Deramoudt; M Szatanik; A Bianchi; P Binder; C Hannoun; J M Alonso
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

3.  Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection.

Authors:  Nayana Prabhu; Mookkan Prabakaran; Hui-Ting Ho; Sumathy Velumani; Jia Qiang; Michael Goutama; Jimmy Kwang
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

4.  Neutralization of respiratory syncytial virus after cell attachment.

Authors:  C Osiowy; R Anderson
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

5.  Probing the flavivirus membrane fusion mechanism by using monoclonal antibodies.

Authors:  Karin Stiasny; Samantha Brandler; Christian Kössl; Franz X Heinz
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

Review 6.  Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development.

Authors:  Zuzana Staneková; Eva Varečková
Journal:  Virol J       Date:  2010-11-30       Impact factor: 4.099

Review 7.  The growth and potential of human antiviral monoclonal antibody therapeutics.

Authors:  Wayne A Marasco; Jianhua Sui
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.